Drug intelligence / Profile preview

U99194

Development stage
Preclinical
Lead developer
Pfizer
Modality
Small Molecules
Administration
Oral, Intravenous (used In Research Animals)
01

Overview

U99194 (often supplied as the maleate salt) is a **potent and moderately selective antagonist of the dopamine D3 receptor**, exhibiting approximately 15-30-fold preference for D3 over the D2 receptor, and more than 10,000-fold selectivity over the D4 receptor. It has been widely used in pharmacological research to probe the role of the D3 receptor in neuropsychiatric conditions and drug addiction. In rodents, U99194 shows **biphasic effects on reward and locomotor activity**, likely due to opposing effects at autoreceptors and postsynaptic receptors. It also affects nociception, thermoregulation, anxiety, learning and memory, and modulates behavioral responses to psychostimulants and opioids. U99194 is not approved for clinical use and is mainly used as a research tool[1][3][5][8].

Other names
U99194 maleateU-99194 maleateU 99194 maleate5,6-dimethoxy-N,N-dipropyl-2,3-dihydro-1H-inden-2-amine fumarate
02

Targets

DRD3 (Dopamine receptor D3)DRD2 (Dopamine D2 Receptor)

Beyond the preview

Go deeper on U99194.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on U99194.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call